QIAGEN fully acquires NeuMoDx Molecular

QIAGEN acquires remaining 80.1% stake in NeuMoDx Molecular, Inc. for $248 million

18-Sep-2020 - QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed after ...

QIAGEN acquires Spanish diagnostics start-up company

QIAGEN enters into agreement to acquire STAT-Dx

09-Feb-2018 - QIAGEN N.V. announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven ...

QIAGEN Acquires DxS Ltd

24-Sep-2009 - QIAGEN N.V. announced that it has acquired DxS Ltd (DxS), a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, United Kingdom. The transaction is valued at approximately US$ 95 million in cash (subject to customary purchase price adjustments), ...

Sports Doping Researchers to Tackle Mount Everest

In the run-up to the Olympics scientists use live mice for the first time on the "roof of the world" to develop new tests for gene doping

28-May-2008 - In the run-up to the Summer Olympics, scientists are taking an innovative approach to develop new molecular testing methods for performance manipulation on the genetic level. A team of researchers from the University of Pennsylvania is attempting to climb Mount Everest, taking with them for the ...

QIAGEN and BioHelix Enter Into Licensing Agreement

Helicase-dependent isothermal DNA amplification system provides new assay technology capabilities for QIAGEN's assay automation platforms

05-May-2008 - QIAGEN and privately held BioHelix have announced that they have entered into a non-exclusive worldwide license and supply agreement for BioHelix's proprietary Helicase Dependent Amplification technology (HDA). HDA is a versatile assay technology to detect and analyze biological target molecules ...

QIAGEN and Bio*One Capital Enter into Joint Venture to Develop Molecular Diagnostics Products

Assay development centre for Singapore will support QIAGEN in the market for molecular testing solutions

05-Dec-2007 - QIAGEN and Bio*One Capital announced that they have entered into a joint venture to establish Dx Assays Pte Ltd ("Dx Assays"). Dx Assays expects to be one of the first centres in Singapore for assay development in which molecular diagnostics for infectious and genetic diseases will be developed. ...

QIAGEN Signs Agreement for the Acquisition of eGene

Strategic Transaction adds Capillary Sample Separation Technology Targeting Molecular Diagnostics and Other Applications

17-Apr-2007 - QIAGEN N.V. announced, that its subsidiary QIAGEN North American Holdings, Inc. has signed a definitive merger agreement with eGene, Inc. pursuant to which eGene would become a fully owned subsidiary of QIAGEN North American Holdings, Inc. eGene is an early-stage company, that has developed and ...

QIAGEN Significantly Expands its Portfolio of Licenses to real-time PCR

Two New Licenses Added to Technology Portfolio targeting Molecular Diagnostics

16-Feb-2007 - QIAGEN N.V. announced that it has acquired licenses from Roche, as well as from Ortho Clinical Diagnostics. According to the company, these two license agreements significantly expand QIAGEN's rights to real-time polymerase chain reaction (PCR) for use in In Vitro Diagnostics (IVD). Financial ...

QIAGEN Acquires Genaco Biomedical Products, Inc.

31-Oct-2006 - QIAGEN N.V. announced that it acquired all outstanding shares of Genaco Biomedical Products, Inc. (Genaco). Genaco is an early-stage company applying a proprietary PCR-based multiplexing technology, Tem-PCR, to develop Templex(TM) molecular diagnostic tests. Genaco is based in Huntsville, ...

QIAGEN Announces Supply Agreement to Provide Preanalytical Solutions to Osmetech Molecular Diagnostics

22-Nov-2005 - QIAGEN GmbH, a wholly-owned subsidiary of QIAGEN N.V. and Osmetech Molecular Diagnostics., a division of Osmetech plc announced that they have entered into a distribution agreement. Pursuant to this agreement, Osmetech will incorporate certain preanalytical consumables and technologies from ...